Circulating Glutamine and Alzheimer’s Disease: A Mendelian Randomization Study
Charleen D Adams Beckman Research Institute, Duarte, CA, USACorrespondence: Charleen D AdamsBeckman Research Institute, City of Hope,1500 E. Duarte Road, Duarte, CA, USATel +1 626-841-3931Fax +1 626-841-9204Email chaadams@coh.orgBackground: Alzheimer’s disease is a devastating neurodegener...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bb265a3e11524b8db97f3a0f8bdf60cf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:bb265a3e11524b8db97f3a0f8bdf60cf |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:bb265a3e11524b8db97f3a0f8bdf60cf2021-12-02T10:43:07ZCirculating Glutamine and Alzheimer’s Disease: A Mendelian Randomization Study1178-1998https://doaj.org/article/bb265a3e11524b8db97f3a0f8bdf60cf2020-02-01T00:00:00Zhttps://www.dovepress.com/circulating-glutamine-and-alzheimers-disease-a-mendelian-randomization-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Charleen D Adams Beckman Research Institute, Duarte, CA, USACorrespondence: Charleen D AdamsBeckman Research Institute, City of Hope,1500 E. Duarte Road, Duarte, CA, USATel +1 626-841-3931Fax +1 626-841-9204Email chaadams@coh.orgBackground: Alzheimer’s disease is a devastating neurodegenerative disorder. Its worldwide prevalence is over 24 million and is expected to double by 2040. Finding ways to prevent its cognitive decline is urgent.Methods: A two-sample Mendelian randomization study was performed instrumenting glutamine, which is abundant in blood, capable of crossing the blood-brain barrier, and involved in a metabolic cycle with glutamate in the brain.Results: The results reveal a protective effect of circulating glutamine against Alzheimer’s disease (inverse-variance weighted method, odds ratio per 1-standard deviation increase in circulating glutamine = 0.83; 95% CI 0.71, 0.97; P = 0.02).Conclusion: These findings lend credence to the emerging story supporting the modifiability of glutamine/glutamate metabolism for the prevention of cognitive decline. More circulating glutamine might mean that more substrate is available during times of stress, acting as a neuroprotectant. Modifications to exogenous glutamine may be worth exploring in future efforts to prevent and/or treat Alzheimer’s disease.Keywords: Alzheimer’s disease, dementia, metabolism, glutamine, Mendelian randomization, preventionAdams CDDove Medical Pressarticlealzheimer’s diseasedementiametabolismglutaminemendelian randomizationpreventionGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 15, Pp 185-193 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
alzheimer’s disease dementia metabolism glutamine mendelian randomization prevention Geriatrics RC952-954.6 |
| spellingShingle |
alzheimer’s disease dementia metabolism glutamine mendelian randomization prevention Geriatrics RC952-954.6 Adams CD Circulating Glutamine and Alzheimer’s Disease: A Mendelian Randomization Study |
| description |
Charleen D Adams Beckman Research Institute, Duarte, CA, USACorrespondence: Charleen D AdamsBeckman Research Institute, City of Hope,1500 E. Duarte Road, Duarte, CA, USATel +1 626-841-3931Fax +1 626-841-9204Email chaadams@coh.orgBackground: Alzheimer’s disease is a devastating neurodegenerative disorder. Its worldwide prevalence is over 24 million and is expected to double by 2040. Finding ways to prevent its cognitive decline is urgent.Methods: A two-sample Mendelian randomization study was performed instrumenting glutamine, which is abundant in blood, capable of crossing the blood-brain barrier, and involved in a metabolic cycle with glutamate in the brain.Results: The results reveal a protective effect of circulating glutamine against Alzheimer’s disease (inverse-variance weighted method, odds ratio per 1-standard deviation increase in circulating glutamine = 0.83; 95% CI 0.71, 0.97; P = 0.02).Conclusion: These findings lend credence to the emerging story supporting the modifiability of glutamine/glutamate metabolism for the prevention of cognitive decline. More circulating glutamine might mean that more substrate is available during times of stress, acting as a neuroprotectant. Modifications to exogenous glutamine may be worth exploring in future efforts to prevent and/or treat Alzheimer’s disease.Keywords: Alzheimer’s disease, dementia, metabolism, glutamine, Mendelian randomization, prevention |
| format |
article |
| author |
Adams CD |
| author_facet |
Adams CD |
| author_sort |
Adams CD |
| title |
Circulating Glutamine and Alzheimer’s Disease: A Mendelian Randomization Study |
| title_short |
Circulating Glutamine and Alzheimer’s Disease: A Mendelian Randomization Study |
| title_full |
Circulating Glutamine and Alzheimer’s Disease: A Mendelian Randomization Study |
| title_fullStr |
Circulating Glutamine and Alzheimer’s Disease: A Mendelian Randomization Study |
| title_full_unstemmed |
Circulating Glutamine and Alzheimer’s Disease: A Mendelian Randomization Study |
| title_sort |
circulating glutamine and alzheimer’s disease: a mendelian randomization study |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/bb265a3e11524b8db97f3a0f8bdf60cf |
| work_keys_str_mv |
AT adamscd circulatingglutamineandalzheimerrsquosdiseaseamendelianrandomizationstudy |
| _version_ |
1718396851712950272 |